Molecular pathology tests
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article is a collection of molecular pathology tests. It is not meant to be complete list. It is there to give a flavour of what is out there and how things are done.
Hereditary
Tests for hereditary conditions:[1]
Target | Technique | Disease | Notes |
---|---|---|---|
F2[2] | PCR | thrombophilia | see Risks for VTE, done together with F5 |
F5[3] | PCR | thrombophilia | see Risks for VTE, done together with F2 |
HFE[4] Cys282Tyr, His63Asp | PCR | hemochromatosis | - |
RYR1 | PCR & sequencing | malignant hyperthermia | anesthetics |
APOA1, TTR, FGA, LYZ | PCR & sequencing | herediary amyloidosis | |
HBA | PCR | Alpha thalassemia |
Lymphoma
Tests for lymphomas:[1]
Target | Technique | Disease | Notes |
---|---|---|---|
BCL2 | PCR | follicular lymphoma vs. follicular hyperplasia | |
several | Southern / PCR | T cell neoplasia | |
Ig heavy chain, Ig light chain | Southern / PCR | B cell neoplasia | |
EBV | PTLD vs. rejection | ||
HHV-8 | PCR | HHV-8 associated lymphomas (body cavity lymphoma, primary effusion lymphoma) |
Leukemia
Tests for leukemias:[1]
Target | Technique | Disease | Notes |
---|---|---|---|
BCR-ABL1 t(9;22) | RQ-PCR | CML, ALL | used to detect residual disease[5] |
MLL-AF4 t(4;11) | RQ-PCR | ||
PML-RARA t(15;17) | RQ-PCR | APL | detect relapse, diagnostic, determines therapy |
RUNX1-RUNX1T1 (AKA AML1/ETO) t(8;21) | RQ-PCR | AML-M2 | good prognosis |
CBFB-MYHII t(16;16) | RQ-PCR | AML-M4Eo | good prognosis |
ETV6-RUNX1 t(12;21) | RQ-PCR | ALL, AML | good prognosis |
FLT3, NPM1 (FLT-3, NPM) | RT-PCR/RE digest | AML | prognostic |
15 STR loci, amelogenin | PCR | chimerism (post-BMT), identity testing | monitor transplants, sort-out mixed-up specimens |
Carcinoma
Tests for carcinomas:[1]
Target | Technique | Disease | Notes |
---|---|---|---|
EBV quantitation | PQ-PCR | Nasopharyngeal carcinoma | |
HPV several | PCR | squamous cell carcinoma (cervix) | |
KRAS, BRAF | fluorescent RFLP, real time PCR, sequencing | metastatic colorectal carcinoma | |
EGRF | fluorescent RFLP | non small cell lung cancer | |
BRAF V600E | ARMS | papillary thyroid carcinoma |
Neuropathology
Common tests in neurooncology practice:
Target | Technique | Disease | Notes |
---|---|---|---|
LOH 1p/19q | PCR | oligodendroglioma | Prognostic and predicts response to PCV treatment.[6] |
IDH1/2 | PCR + IDH1 R132H antibody. | oligodendroglioma & astrocytoma. | Diagnostic and prognostic.[7] |
H3F3A | PCR + H3.3 K27M antibody. | glioblastoma & astrocytoma. | Diagnostic (K27M-mutant glioma of the midline / pediatric glioblastoma). [8] |
MGMT | Methylation-specific PCR, Pyroseq. | glioblastoma, astrocytoma & oligodendroglioma. | Prognostic & predicts treatment to Temozolomide treatment.[9] |
BRAF-Fusion | RT-PCR, RNAseq + Defuse-Analysis[10] | pilocytic astrocytoma | Diagnostic.[11] |
Rela-Fusion | RT-PCR, RNAseq + Defuse-Analysis | supratentorial ependymoma | Diagnostic and prognostic (unfavourable, when present).[12] |
Other
Tests for miscellaneous things:[1]
Target | Technique | Disease | Notes |
---|---|---|---|
15 STRs and amelogenin (XY) loci | PCR[13] | identity testing - chimerism analysis (post-BMT),[14] specimen mix-ups, decendent identification/evidence (forensic pathology) | |
KIT, BRAF | sequencying, ARMS | malignant melanoma | |
several | PQ-PCR | synovial sarcoma | |
JAK2 V617F | ARMS | myeloproliferative disorders | |
KIT | sequencing | AML, mastocytosis, GIST |
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 University Health Network. Molecular diagnostics - current testing. Document number: PMD10002. Version 2.0. March 30, 2011.
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 176930
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 612309
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 613609
- ↑ Mitchell, Richard; Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Aster, Jon (2011). Pocket Companion to Robbins & Cotran Pathologic Basis of Disease (8th ed.). Elsevier Saunders. pp. 175. ISBN 978-1416054542.
- ↑ Cairncross, G.; Wang, M.; Shaw, E.; Jenkins, R.; Brachman, D.; Buckner, J.; Fink, K.; Souhami, L. et al. (Jan 2013). "Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.". J Clin Oncol 31 (3): 337-43. doi:10.1200/JCO.2012.43.2674. PMID 23071247.
- ↑ Hartmann, C.; Hentschel, B.; Wick, W.; Capper, D.; Felsberg, J.; Simon, M.; Westphal, M.; Schackert, G. et al. (Dec 2010). "Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.". Acta Neuropathol 120 (6): 707-18. doi:10.1007/s00401-010-0781-z. PMID 21088844.
- ↑ Sturm, D.; Witt, H.; Hovestadt, V.; Khuong-Quang, DA.; Jones, DT.; Konermann, C.; Pfaff, E.; Tönjes, M. et al. (Oct 2012). "Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.". Cancer Cell 22 (4): 425-37. doi:10.1016/j.ccr.2012.08.024. PMID 23079654.
- ↑ Stupp, R.; Hegi, ME.; Mason, WP.; van den Bent, MJ.; Taphoorn, MJ.; Janzer, RC.; Ludwin, SK.; Allgeier, A. et al. (May 2009). "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.". Lancet Oncol 10 (5): 459-66. doi:10.1016/S1470-2045(09)70025-7. PMID 19269895.
- ↑ McPherson, A.; Hormozdiari, F.; Zayed, A.; Giuliany, R.; Ha, G.; Sun, MG.; Griffith, M.; Heravi Moussavi, A. et al. (May 2011). "deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.". PLoS Comput Biol 7 (5): e1001138. doi:10.1371/journal.pcbi.1001138. PMID 21625565.
- ↑ Hasselblatt, M.; Riesmeier, B.; Lechtape, B.; Brentrup, A.; Stummer, W.; Albert, FK.; Sepehrnia, A.; Ebel, H. et al. (Dec 2011). "BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults.". Neuropathol Appl Neurobiol 37 (7): 803-6. doi:10.1111/j.1365-2990.2011.01193.x. PMID 21696415.
- ↑ Parker, M.; Mohankumar, KM.; Punchihewa, C.; Weinlich, R.; Dalton, JD.; Li, Y.; Lee, R.; Tatevossian, RG. et al. (Feb 2014). "C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.". Nature 506 (7489): 451-5. doi:10.1038/nature13109. PMID 24553141.
- ↑ Romsos, EL.; Vallone, PM. (Apr 2015). "Rapid PCR of STR markers: Applications to human identification.". Forensic Sci Int Genet. doi:10.1016/j.fsigen.2015.04.008. PMID 25937291.
- ↑ Borrill, V.; Schlaphoff, T.; du Toit, E.; Marx, M.; Wood, L.; Jacobs, P. (Aug 2008). "The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report.". Hematology 13 (4): 210-4. doi:10.1179/102453308X316059. PMID 18796246.